Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study
| Autor: | Yahya Mohzari, Mushira Enani, Asma S. Albujaidya, Bandar Alosaimi, Nada M. Alkhani, Ahmed A. Alrashed, Mona A. Alanazi, Amal Ben-Akresh, Ahmad Alamer, Tahir Mehmood Khan, Syed Mohammed Basheeruddin Asdaq, Ivo Abraham, Malak Almutairi, Wafa Alfahad, Maram M. Alghalbi, Noara Alhusseini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Angiotensin-Converting Enzyme Inhibitors Disease Infectious and parasitic diseases RC109-216 Logistic regression MOH Ministry of Health law.invention IPSW Inverse propensity score weighting 0302 clinical medicine law ACEI Angiotensin-converting enzyme inhibitors RAAS Renin-angiotensin-aldosterone system 030212 general & internal medicine Confounding General Medicine Intensive care unit Hospitals ICU Intensive care unit Infectious Diseases MV Mechanical ventilation ARB Angiotensin receptor blockers SARS-CoV-2 Severe acute respiratory syndrome coronavirus Public aspects of medicine RA1-1270 medicine.medical_specialty COVID-19 Coronavirus disease 2019 Referral 030106 microbiology NIV Non-invasive ventilation Saudi Arabia LOVD Leiden open variation database Article WHO World Health Organization Angiotensin Receptor Antagonists 03 medical and health sciences Internal medicine Diabetes mellitus medicine Humans cardiovascular diseases Mortality Disease severity Retrospective Studies SARS-CoV-2 business.industry Public Health Environmental and Occupational Health COVID-19 Retrospective cohort study PSM Propensity score matching medicine.disease Hospital admission Angiotensin-converting enzyme inhibitor Propensity score matching Angiotensin II receptor blocker business OR Odds ratio RT-PCR Real-time polymerase chain reaction (RT-PCR) |
| Zdroj: | Journal of Infection and Public Health, Vol 14, Iss 6, Pp 726-733 (2021) Journal of Infection and Public Health |
| ISSN: | 1876-0341 |
| Popis: | Background The uncertainty about COVID-19 outcomes in angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. This study aimed to determine the effect of ACEI/ARB use in patients with severe COVID-19. Methods This retrospective cohort study was done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with a confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. Controlling for confounders, we conducted multivariate logistic regression and sensitivity analyses using propensity score matching (PSM) and Inverse propensity score weighting (IPSW) for high-risk patient subsets. Results Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR = 8.25, 95%CI = 3.32–20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR = 6.76, 95%CI = 2.88–15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR = 4.77,95%CI = 2.15–10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR = 5.40,95%CI = 2.0−14.54]. These results were confirmed in the PSM and IPSW analyses. Conclusion In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|